Kexon Pharmaceuticals: Passed EU GMP certification
Glonghui, May 5 | Kexon Pharmaceuticals announced that it recently received the “Pharmaceutical GMP Certificate” issued by the Norwegian Medicines Agency in accordance with relevant regulations of the European Medicines Agency. The certified product is paclitaxel for injection (albumin binding type) (5 mg/ml). Injectable paclitaxel (albumin binding) is the mainstream first-line medication recommended by the European Society of Medical Oncology guidelines for the treatment of metastatic pancreatic cancer and non-small cell lung cancer. According to the GMP mutual recognition system among EU member states, passing the GMP certification this time indicates that the production line that has been certified has met EU GMP standards, and the company has paclitaxel (albumin binding) products for injection
Kexing Pharmaceuticals (688136.SH): Repurchased a total of 1.308,200 shares of the company's shares
Gelonghui May 5 丨 Kexon Pharmaceuticals (688136.SH) issued an announcement that the company did not repurchase shares in April 2024. As of April 30, 2024, the company has repurchased a total of 1.3082 million shares of the company through centralized bidding transactions through the Shanghai Stock Exchange trading system, accounting for 0.66% of the company's total share capital. The highest price of the repurchase transaction was 16.77 yuan/share, the lowest price was 14.30 yuan/share, and the total amount of capital paid was RMB 199,973 million (not including transaction fees).
Conn Bay (600572.SH): Cumulative repurchase of 51.45 million shares of the company
Glonghui, May 5, 丨 Conn Bay (600572.SH) announced that as of April 30, 2024, the company had repurchased a total of 51.46.45 million shares of the company's shares through centralized bidding transactions at the Shanghai Stock Exchange, accounting for 2.00% of the company's total share capital. The highest repurchase transaction price was 5.00 yuan/share, the lowest price was 4.08 yuan/share, and the total capital commission used was 245.9663 million yuan (excluding transaction fees such as stamp duty and transaction fees).
Kexon Pharmaceuticals (688136.SH): Paclitaxel for injection (albumin binding type) has passed EU GMP certification
Kexon Pharmaceuticals (688136.SH) issued an announcement. The company recently received from the Norwegian Drug Administration according to the European Drug Administration...
Dongcheng Pharmaceutical (002675): Performance fluctuations due to heparin APIs, innovative nuclear drugs are expected to reap
The 2023 results are lower than our expectations. The company announced the results for the first quarter of 2023 and 2024: in 2023, the company's revenue was 3.28 billion yuan, down 8.6% year on year, in line with our expectations; net profit due to mother 2.1
Express News | Northeast Pharmaceutical: Sun Company obtained registration certificate for injectable azithromycin